CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...
Phase 1, Phase 2
Rome, Italy and 26 other locations
\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...
Phase 3
Roma, Rome, Italy and 85 other locations
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...
Phase 3
Rome, Italy and 160 other locations
will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has ...
Phase 1, Phase 2
Roma, Italy and 55 other locations
Older patients with acute myeloid leukemia (AML) have a small (\< 10%) chance of long-term survival. Despite the ...
Phase 3
Rome, Italy and 52 other locations
when administered to adult patients with relapsed or refractory acute myeloid leukemia (AML) or relapsed or progr...
Phase 2
Roma, Italy and 40 other locations
with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitr...
Phase 1, Phase 2
Roma, Italy and 48 other locations
chemotherapy with low intensity therapies in 1st or 2nd relapse Acute Myeloid Leukemia. The study is funded by European Co...
Phase 3
Roma, RM, Italy and 33 other locations
participants with AML.The duration of this multi-phase study is approximately 7 years....
Phase 2, Phase 3
Roma, Italy and 71 other locations
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible f...
Phase 3
Rome, Italy and 171 other locations
Clinical trials
Research sites
Resources
Legal